Oklahoma Planning Grant for Clinical /Translational Scie

描述（由申请人提供）：俄克拉何马大学健康科学中心（俄克拉何马城和塔尔萨）、俄克拉何马大学诺曼校区和俄克拉何马医学研究基金会正在扩大他们在跨学科临床和转化科学方面的努力。利用我们现有的三个合作伙伴使用的一般临床研究中心（GCRC），我们计划的临床和转化科学奖（CTSA）的目标是制定一个全面的战略，以建立临床研究基础设施和培训。关于国家CTSA网络，我们的地方努力将在美洲土著健康研究、医学人类学和基于实践的研究方面带来特殊优势。在完成了激烈的SWOT（优势、劣势、机会和威胁）分析后，我们寻求计划资金来增加CTSA的所有九个建议元素。规划过程将特别侧重于定量科学，即设计、生物统计学和生物医学信息学（DBBI），以证明大型CTSA企业的可行性。我们已经建立了一个CTSA执行委员会（四名GCRC领导人），以及一个咨询委员会，包括所有八名院长和健康科学中心的教务长，来自俄克拉何马州医学研究基金会的临床科学家，医学博士/博士。她是俄勒冈州立大学癌症研究所和俄克拉何马州糖尿病中心的主任，也是一名评估员，他是负责教师发展和跨学科项目的副教务长。五位个人和全国知名专家将分别访问1.5天，以说明临床和转化科学的科学成功，并对我们的发展发表评论。CTS将成立课程和DBBI小组委员会，以完善这两个关键领域的发展并开展扩展。临床研究博士和硕士学位将由研究生院管理，并由活跃的临床研究者指导。将进行持续的定性和定量项目评估。

DESCRIPTION (provided by applicant): The University of Oklahoma Health Sciences Center (Oklahoma City and Tulsa), the University of Oklahoma Norman Campus, and the Oklahoma Medical Research Foundation are expanding their efforts in interdisciplinary clinical and translational science. Leveraged on our existing General Clinical Research Center (GCRC) used by all three partners, our objective in planning for a Clinical and Translational Science Award (CTSA) is to develop a comprehensive strategy to build clinical research infrastructure and training. With respect to national CTSA network, our local efforts will bring special strengths in Native American health research, medical anthropology, and practice-based research. Having completed an intense SWOT (Strengths, Weaknesses, Opportunities, and Threats) analysis, we seek planning funds to augment all nine suggested elements of a CTSA. The planning process will focus in particular on quantitative sciences, namely Design, Biostatistics, and Biomedical Informatics (DBBI), to demonstrate the feasibility of the larger CTSA enterprise. We have established a CTSA Executive Committee (four GCRC leaders), as well as an Advisory Council, including all eight Deans and the Provost of the Health Sciences Center, a clinical scientist from the Oklahoma Medical Research Foundation, an M.D./Ph.D. student, Directors of the OU Cancer Institute and the Oklahoma Diabetes Center, and an evaluator, who is Associate Vice-Provost for Faculty Development and Interdisciplinary Programs. Five individual and nationally prominent experts will visit for 1.5 days each to illustrate scientific success in clinical and translational science and to comment on our developments. CTS subcommittees on Curriculum and DBBI will be established to refine developments and launch expansion in those two crucial areas. Ph.D. and M.S. degrees in Clinical Investigation will be administered by the Graduate College and mentored by active clinical investigators. Ongoing qualitative and quantitative program evaluation will be conducted.